HALO logo
halo search icon
C4 Therapeutics, Inc.

US$3.52

Price Change Indicator
0.24 (7.32%)
C4 Therapeutics, Inc.
CCCC · NAS

C4 Therapeutics, Inc.

Start Trading CCCC for Free

US$3.52

Price Arrow0.24 (7.32%)
21/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig CandleBig Candle (Realtime)HALO AllHALO Consensus ValueHALO Earnings MomentumHALO Momentum+1
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

C4 Therapeutics, Inc. Overview

CCCC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About CCCC

icon
icon

Telephone

1.617.231.0700

icon

Address

Suite 120, 490 Arsenal Way, Watertown, MA 02472

Description

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

CCCC Price Chart

Key Stats

Market Cap

US$362.66M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.21 - 3.95

Trade Value (12mth)

US$1,277,936.00

1 week

-7.87%

1 month

6.84%

YTD

69.95%

1 year

139.42%

All time high

51.21

Key Fundamentals

EPS 3 yr Growth

-51.70%

EBITDA Margin

-268.50%

Operating Cashflow

-$99m

Free Cash Flow Return

-33.70%

ROIC

-35.80%

Interest Coverage

0.00

Quick Ratio

7.80

Other Data

Shares Outstanding (Fully Diluted)

126m

HALO Sector

Healthcare

Next Company Report Date

25-Feb-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

CCCC Announcements

Latest Announcements

DateAnnouncements
16 May 26
16 May 26
12 May 26
12 May 26
12 May 26

CCCC Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock-2.67-1.52-1.27locklocklock
EPS (Fully Diluted)
 $locklocklocklock-2.67-1.52-1.27locklocklock
Growth
 %locklocklocklock-1.743.116.6locklocklock
PE
 XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
 XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of C4 Therapeutics, Inc. (CCCC:NAS)?
Halo FAQ
The current share price of C4 Therapeutics, Inc. (CCCC:NAS) is USD$3.52.
What is the 52-week high share price for C4 Therapeutics, Inc. (CCCC:NAS)?
Halo FAQ
The 52-week high share price for C4 Therapeutics, Inc. (CCCC:NAS) is USD$3.95.
What is the 52-week low share price for C4 Therapeutics, Inc. (CCCC:NAS)?
Halo FAQ
The 52-week low share price for C4 Therapeutics, Inc. (CCCC:NAS) is USD$1.21.
What is the dividend yield for C4 Therapeutics, Inc. (CCCC:NAS)?
Halo FAQ
C4 Therapeutics, Inc. (CCCC:NAS) does not pay a dividend.
What was C4 Therapeutics, Inc. (CCCC:NAS) last dividend payment?
Halo FAQ
C4 Therapeutics, Inc. (CCCC:NAS) does not pay a dividend.
What is the franking level for C4 Therapeutics, Inc. (CCCC:NAS)?
Halo FAQ
C4 Therapeutics, Inc. (CCCC:NAS) has a franking level of 0.00%.
In which sector is C4 Therapeutics, Inc. (CCCC:NAS) classified?
Halo FAQ
C4 Therapeutics, Inc. (CCCC:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial